BioMarin Pharmaceutical Inc. (BMRN) has a consensus analyst rating of Buy, based on 41 analysts covering the stock. Of those, 28 recommend buying, 13 recommend holding, and 0 recommend selling.
The analyst consensus price target for BMRN is $86.60, representing a +56.1% upside from the current price of $55.47. Price targets range from a low of $60.00 to a high of $105.00.
